UK payer needs for new device reimbursement
Challenge:
A US medical device company wanted to understand how UK payers would view their technology. They engaged Alacrita to find out.
Solution:
We carried out desk research to develop the technology’s value proposition. We then convened a payer advisory board, comprising a member of the National Institute for Health and Care Excellence (NICE), a director of NHS commissioning as well as payers from regional NHS trusts to understand on what basis payers would evaluate the technology, what comparators would be used and to assess payers’ reactions to the proposed data package based on the currently designed clinical trial and supporting information. We presented a better understanding of the evidence payers require to approve a new medical intervention and provided clear recommendations as to how the company should collect that data.
Related Case Studies
Explore similar engagements and see how we've helped other clients achieve their goals.
Evaluating the Commercial Viability of a Novel Neonatal Therapy Approach
Landscape Assessment of Novel Pain Targets for R&D Prioritization
Axl/merTK target assessment for an AI-driven drug discovery company
Technical Feasibility Ranking of Gene Therapies for CNS Diseases
Interested in Learning More?
Contact us to discuss how we can support your project with similar expertise.